Terug
39
59
Ook genoteerd als
SNN
NYSE
Dagbereik
€ 16,05
€ 16,50
52-Weeksbereik
€ 12,55
€ 18,50
Volume
2.700
50D / 200D Gem.
€ 17,02
/
€ 16,45
Vorige Slotkoers
€ 16,05
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (633 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 21,9 | 0,2 |
| P/B | 2,6 | 2,8 |
| ROE % | 12,1 | 3,7 |
| Net Margin % | 10,1 | 3,9 |
| Rev Growth 5Y % | 4,9 | 10,0 |
| D/E | 0,6 | 0,2 |
Dividend History
Yield
0,02%
Payout Ratio
N/A
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Belangrijkste Punten
Revenue grew 4,86% annually over 5 years — modest growth
Earnings grew 55,07% over the past year
ROE of 12,10% — decent returns on equity
Generating 870,95M in free cash flow
PEG of 0,39 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,59%
Groei
Revenue Growth (5Y)
4,86%
Revenue (1Y)8,45%
Earnings (1Y)55,07%
FCF Growth (3Y)119,36%
Kwaliteit
Return on Equity
12,10%
ROIC8,91%
Net Margin10,14%
Op. Margin16,27%
Veiligheid
Debt / Equity
0,63
Current Ratio2,57
Interest Coverage6,43
Waardering
P/E Ratio
21,93
Forward P/EN/A
P/B Ratio2,64
EV/EBITDA16,37
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8,45% | Revenue Growth (3Y) | 6,56% |
| Earnings Growth (1Y) | 55,07% | Earnings Growth (3Y) | 55,86% |
| Revenue Growth (5Y) | 4,86% | Earnings Growth (5Y) | 5,08% |
| Profitability | |||
| Revenue (TTM) | 6,30B | Net Income (TTM) | 638,90M |
| ROE | 12,10% | ROA | 6,10% |
| Gross Margin | 68,01% | Operating Margin | 16,27% |
| Net Margin | 10,14% | Free Cash Flow (TTM) | 870,95M |
| ROIC | 8,91% | FCF Growth (3Y) | 119,36% |
| Safety | |||
| Debt / Equity | 0,63 | Current Ratio | 2,57 |
| Interest Coverage | 6,43 | ||
| Dividends | |||
| Dividend Yield | 0,02% | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 21,93 | Forward P/E | N/A |
| P/B Ratio | 2,64 | P/S Ratio | 2,22 |
| PEG Ratio | 0,39 | Forward PEG | N/A |
| EV/EBITDA | 16,37 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 6,22% | ||
| Market Cap | 14,01B | Enterprise Value | 16,78B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6,30B | 5,81B | 5,55B | 5,22B | 5,21B |
| Net Income | 638,90M | 412,00M | 263,00M | 223,00M | 524,00M |
| EPS (Diluted) | 0,73 | 0,47 | 0,30 | 0,26 | 0,59 |
| Gross Profit | 4,29B | 4,05B | 3,82B | 3,68B | 3,67B |
| Operating Income | 1,03B | 657,00M | 425,00M | 450,00M | 593,00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 10,47B | 10,35B | 9,99B | 9,97B | 10,92B |
| Total Liabilities | 5,18B | 5,09B | 4,77B | 4,71B | 5,35B |
| Shareholders' Equity | 5,30B | 5,27B | 5,22B | 5,26B | 5,57B |
| Total Debt | 3,33B | 3,32B | 3,08B | 2,87B | 3,34B |
| Cash & Equivalents | 557,89M | 619,00M | 302,00M | 350,00M | 1,29B |
| Current Assets | 4,11B | 4,42B | 4,03B | 3,86B | 4,42B |
| Current Liabilities | 1,60B | 1,53B | 2,27B | 1,72B | 2,13B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#633 of 1058
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#111 of 330
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026